-transparent.png){kind=logo}
In vitro effect of Dilazep on the release and metabolism of arachidonic acid (AA) in human platelets was studied. Dilazep reduced in a dose-dependent manner platelet aggregation and thromboxane B2 (TXB2) formation when stimulated by adenosine diphosphate, collagen and epinephrine. Dilazep decreased thrombin-induced release of [14C]arachidonic acid ([14C]AA) from platelets prelabeled with [14C]AA. The conversion of [14C]AA to cyclooxygenase metabolites was reduced by the addition of Dilazep, while that to 12-lipoxygenase metabolite was rather increased. Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate levels in washed human platelets were not affected by the addition of Dilazep. These results suggest that the decreased TXB2 formation by Dilazep may be ascribed to the impairment of AA release from platelet membrane phospholipids and the reduced conversion of released AA to TXA2.
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
March 1980,
La Clinica terapeutica,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
December 1976,
Revista espanola de fisiologia,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
October 1981,
Biochemical pharmacology,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
January 1979,
La Nouvelle presse medicale,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
January 1966,
Hemostase,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
February 1985,
Blood,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
May 1987,
Pharmacological research communications,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
April 1980,
Agents and actions,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
October 1980,
Minerva cardioangiologica,
M Takenaga, and
H Kitagawa, and
A Hirai, and
Y Tamura, and
S Yoshida
August 2006,
Biochemical pharmacology,
